Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and therapy of the disease
- Autores
- Llauradó, Marta; Ruiz, Anna; Majem, Blanca; Ertekin, Tugce; Colás, Eva; Pedrola, Nuria; Devis, Laura; Rigau, Marina; Sequeiros, Tamara; Montes, Melania; Garcia, Marta; Cabrera, Sílvia; Gil Moreno, Antonio; Xercavins, Jordi; Castellví, Josep; Garcia, Angel; Ramón y Cajal, Santiago; Moreno, Gema; Alameda, Francesc; Vazquez, Monica Hebe; Palacios, José; Prat, Jaime; Doll, Andreas; Matías Guiu, Xavier; Abal, Miguel; Reventós, Jaume
- Año de publicación
- 2011
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Endometrial carcinoma (EC) is the most commonly diagnosed gynecologic malignancy in the western world. The majority of these cancers are curable, but a subset about 15–20% of endometrial tumors exhibits an aggressive phenotype. Based on clinic-pathological and molecular characteristics, EC has been classified into two groups: Type I estrogen-dependent adenocarcinomas, which have a good prognosis and an endometrioid histology, and Type II or non-estrogen-dependent EC associated with poor prognosis and non-endometrioid histology. EC develops as a result of a stepwise accumulation of alterations that seem to be specific of each histological type. However, more knowledge is needed to better understand the differences in the biology and the clinical outcome of EC. We would like to highlight the need to explore new potential biomarkers of EC as a tool for the detection and monitoring of aggressive endometrial tumors that, at the same time, will allow us to develop novel and more selective molecular targeted therapies against EC.
Fil: Llauradó, Marta. Universidad Autonoma de Barcelona. Hospital Vall D; España
Fil: Ruiz, Anna. Universidad Autonoma de Barcelona. Hospital Vall D; España
Fil: Majem, Blanca. Universidad Autonoma de Barcelona. Hospital Vall D; España
Fil: Ertekin, Tugce. Universidad Autonoma de Barcelona. Hospital Vall D; España
Fil: Colás, Eva. Universidad Autonoma de Barcelona. Hospital Vall D; España
Fil: Pedrola, Nuria. Universidad Autonoma de Barcelona. Hospital Vall D; España
Fil: Devis, Laura. Universidad Autonoma de Barcelona. Hospital Vall D; España
Fil: Rigau, Marina. Universidad Autonoma de Barcelona. Hospital Vall D; España
Fil: Sequeiros, Tamara. Universidad Autonoma de Barcelona. Hospital Vall D; España
Fil: Montes, Melania. Universidad Autonoma de Barcelona. Hospital Vall D; España
Fil: Garcia, Marta. Universidad Autonoma de Barcelona. Hospital Vall D; España
Fil: Cabrera, Sílvia. Universidad Autonoma de Barcelona. Hospital Vall D; España
Fil: Gil Moreno, Antonio. Universidad Autonoma de Barcelona. Hospital Vall D; España
Fil: Xercavins, Jordi. Universidad Autonoma de Barcelona. Hospital Vall D; España
Fil: Castellví, Josep. Universidad Autonoma de Barcelona. Hospital Vall D; España
Fil: Garcia, Angel. Universidad Autonoma de Barcelona. Hospital Vall D; España
Fil: Ramón y Cajal, Santiago. Universidad Autonoma de Barcelona. Hospital Vall D; España
Fil: Moreno, Gema. Fundación MD Anderson; España
Fil: Alameda, Francesc. Hospital del Mar. Servei de Patologia ; España
Fil: Vazquez, Monica Hebe. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); Argentina. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Centro Cientifico Tecnológico Bahia Blanca. Instituto de Ciencias Biologicas y Biomedicas del Sur; Argentina
Fil: Palacios, José. Universidad Autonoma de Barcelona. Hospital Vall D; España
Fil: Prat, Jaime. Hospital de la Santa Creu i Sant Pau. Servei de Patologia; España
Fil: Doll, Andreas. Universidad Autonoma de Barcelona. Hospital Vall D; España
Fil: Matías Guiu, Xavier. Hospital Arnau de Vilanova. Servei de Patologia; España
Fil: Abal, Miguel. Complejo Hospitalario de Santiago de Compostela; España
Fil: Reventós, Jaume. Universidad Autonoma de Barcelona. Hospital Vall D; España - Materia
-
Endometrial Carcinoma
Molecular Genetics
Treatment
Target Therapy
Aspirates
Mice - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
- Repositorio
.jpg)
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/11208
Ver los metadatos del registro completo
| id |
CONICETDig_b9ed741cd47fd2df9bc80923f2cdeb0c |
|---|---|
| oai_identifier_str |
oai:ri.conicet.gov.ar:11336/11208 |
| network_acronym_str |
CONICETDig |
| repository_id_str |
3498 |
| network_name_str |
CONICET Digital (CONICET) |
| spelling |
Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and therapy of the diseaseLlauradó, MartaRuiz, AnnaMajem, BlancaErtekin, TugceColás, EvaPedrola, NuriaDevis, LauraRigau, MarinaSequeiros, TamaraMontes, MelaniaGarcia, MartaCabrera, SílviaGil Moreno, AntonioXercavins, JordiCastellví, JosepGarcia, AngelRamón y Cajal, SantiagoMoreno, GemaAlameda, FrancescVazquez, Monica HebePalacios, JoséPrat, JaimeDoll, AndreasMatías Guiu, XavierAbal, MiguelReventós, JaumeEndometrial CarcinomaMolecular GeneticsTreatmentTarget TherapyAspiratesMicehttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Endometrial carcinoma (EC) is the most commonly diagnosed gynecologic malignancy in the western world. The majority of these cancers are curable, but a subset about 15–20% of endometrial tumors exhibits an aggressive phenotype. Based on clinic-pathological and molecular characteristics, EC has been classified into two groups: Type I estrogen-dependent adenocarcinomas, which have a good prognosis and an endometrioid histology, and Type II or non-estrogen-dependent EC associated with poor prognosis and non-endometrioid histology. EC develops as a result of a stepwise accumulation of alterations that seem to be specific of each histological type. However, more knowledge is needed to better understand the differences in the biology and the clinical outcome of EC. We would like to highlight the need to explore new potential biomarkers of EC as a tool for the detection and monitoring of aggressive endometrial tumors that, at the same time, will allow us to develop novel and more selective molecular targeted therapies against EC.Fil: Llauradó, Marta. Universidad Autonoma de Barcelona. Hospital Vall D; EspañaFil: Ruiz, Anna. Universidad Autonoma de Barcelona. Hospital Vall D; EspañaFil: Majem, Blanca. Universidad Autonoma de Barcelona. Hospital Vall D; EspañaFil: Ertekin, Tugce. Universidad Autonoma de Barcelona. Hospital Vall D; EspañaFil: Colás, Eva. Universidad Autonoma de Barcelona. Hospital Vall D; EspañaFil: Pedrola, Nuria. Universidad Autonoma de Barcelona. Hospital Vall D; EspañaFil: Devis, Laura. Universidad Autonoma de Barcelona. Hospital Vall D; EspañaFil: Rigau, Marina. Universidad Autonoma de Barcelona. Hospital Vall D; EspañaFil: Sequeiros, Tamara. Universidad Autonoma de Barcelona. Hospital Vall D; EspañaFil: Montes, Melania. Universidad Autonoma de Barcelona. Hospital Vall D; EspañaFil: Garcia, Marta. Universidad Autonoma de Barcelona. Hospital Vall D; EspañaFil: Cabrera, Sílvia. Universidad Autonoma de Barcelona. Hospital Vall D; EspañaFil: Gil Moreno, Antonio. Universidad Autonoma de Barcelona. Hospital Vall D; EspañaFil: Xercavins, Jordi. Universidad Autonoma de Barcelona. Hospital Vall D; EspañaFil: Castellví, Josep. Universidad Autonoma de Barcelona. Hospital Vall D; EspañaFil: Garcia, Angel. Universidad Autonoma de Barcelona. Hospital Vall D; EspañaFil: Ramón y Cajal, Santiago. Universidad Autonoma de Barcelona. Hospital Vall D; EspañaFil: Moreno, Gema. Fundación MD Anderson; EspañaFil: Alameda, Francesc. Hospital del Mar. Servei de Patologia ; EspañaFil: Vazquez, Monica Hebe. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); Argentina. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Centro Cientifico Tecnológico Bahia Blanca. Instituto de Ciencias Biologicas y Biomedicas del Sur; ArgentinaFil: Palacios, José. Universidad Autonoma de Barcelona. Hospital Vall D; EspañaFil: Prat, Jaime. Hospital de la Santa Creu i Sant Pau. Servei de Patologia; EspañaFil: Doll, Andreas. Universidad Autonoma de Barcelona. Hospital Vall D; EspañaFil: Matías Guiu, Xavier. Hospital Arnau de Vilanova. Servei de Patologia; EspañaFil: Abal, Miguel. Complejo Hospitalario de Santiago de Compostela; EspañaFil: Reventós, Jaume. Universidad Autonoma de Barcelona. Hospital Vall D; EspañaElsevier Ireland2011-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/11208Llauradó, Marta; Ruiz, Anna; Majem, Blanca; Ertekin, Tugce; Colás, Eva; et al.; Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and therapy of the disease; Elsevier Ireland; Molecular And Cellular Endocrinology; 358; 2; 10-2011; 244-2550303-7207enginfo:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S0303720711005892info:eu-repo/semantics/altIdentifier/doi/10.1016/j.mce.2011.10.003info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:54:25Zoai:ri.conicet.gov.ar:11336/11208instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:54:26.272CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
| dc.title.none.fl_str_mv |
Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and therapy of the disease |
| title |
Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and therapy of the disease |
| spellingShingle |
Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and therapy of the disease Llauradó, Marta Endometrial Carcinoma Molecular Genetics Treatment Target Therapy Aspirates Mice |
| title_short |
Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and therapy of the disease |
| title_full |
Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and therapy of the disease |
| title_fullStr |
Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and therapy of the disease |
| title_full_unstemmed |
Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and therapy of the disease |
| title_sort |
Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and therapy of the disease |
| dc.creator.none.fl_str_mv |
Llauradó, Marta Ruiz, Anna Majem, Blanca Ertekin, Tugce Colás, Eva Pedrola, Nuria Devis, Laura Rigau, Marina Sequeiros, Tamara Montes, Melania Garcia, Marta Cabrera, Sílvia Gil Moreno, Antonio Xercavins, Jordi Castellví, Josep Garcia, Angel Ramón y Cajal, Santiago Moreno, Gema Alameda, Francesc Vazquez, Monica Hebe Palacios, José Prat, Jaime Doll, Andreas Matías Guiu, Xavier Abal, Miguel Reventós, Jaume |
| author |
Llauradó, Marta |
| author_facet |
Llauradó, Marta Ruiz, Anna Majem, Blanca Ertekin, Tugce Colás, Eva Pedrola, Nuria Devis, Laura Rigau, Marina Sequeiros, Tamara Montes, Melania Garcia, Marta Cabrera, Sílvia Gil Moreno, Antonio Xercavins, Jordi Castellví, Josep Garcia, Angel Ramón y Cajal, Santiago Moreno, Gema Alameda, Francesc Vazquez, Monica Hebe Palacios, José Prat, Jaime Doll, Andreas Matías Guiu, Xavier Abal, Miguel Reventós, Jaume |
| author_role |
author |
| author2 |
Ruiz, Anna Majem, Blanca Ertekin, Tugce Colás, Eva Pedrola, Nuria Devis, Laura Rigau, Marina Sequeiros, Tamara Montes, Melania Garcia, Marta Cabrera, Sílvia Gil Moreno, Antonio Xercavins, Jordi Castellví, Josep Garcia, Angel Ramón y Cajal, Santiago Moreno, Gema Alameda, Francesc Vazquez, Monica Hebe Palacios, José Prat, Jaime Doll, Andreas Matías Guiu, Xavier Abal, Miguel Reventós, Jaume |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Endometrial Carcinoma Molecular Genetics Treatment Target Therapy Aspirates Mice |
| topic |
Endometrial Carcinoma Molecular Genetics Treatment Target Therapy Aspirates Mice |
| purl_subject.fl_str_mv |
https://purl.org/becyt/ford/1.6 https://purl.org/becyt/ford/1 |
| dc.description.none.fl_txt_mv |
Endometrial carcinoma (EC) is the most commonly diagnosed gynecologic malignancy in the western world. The majority of these cancers are curable, but a subset about 15–20% of endometrial tumors exhibits an aggressive phenotype. Based on clinic-pathological and molecular characteristics, EC has been classified into two groups: Type I estrogen-dependent adenocarcinomas, which have a good prognosis and an endometrioid histology, and Type II or non-estrogen-dependent EC associated with poor prognosis and non-endometrioid histology. EC develops as a result of a stepwise accumulation of alterations that seem to be specific of each histological type. However, more knowledge is needed to better understand the differences in the biology and the clinical outcome of EC. We would like to highlight the need to explore new potential biomarkers of EC as a tool for the detection and monitoring of aggressive endometrial tumors that, at the same time, will allow us to develop novel and more selective molecular targeted therapies against EC. Fil: Llauradó, Marta. Universidad Autonoma de Barcelona. Hospital Vall D; España Fil: Ruiz, Anna. Universidad Autonoma de Barcelona. Hospital Vall D; España Fil: Majem, Blanca. Universidad Autonoma de Barcelona. Hospital Vall D; España Fil: Ertekin, Tugce. Universidad Autonoma de Barcelona. Hospital Vall D; España Fil: Colás, Eva. Universidad Autonoma de Barcelona. Hospital Vall D; España Fil: Pedrola, Nuria. Universidad Autonoma de Barcelona. Hospital Vall D; España Fil: Devis, Laura. Universidad Autonoma de Barcelona. Hospital Vall D; España Fil: Rigau, Marina. Universidad Autonoma de Barcelona. Hospital Vall D; España Fil: Sequeiros, Tamara. Universidad Autonoma de Barcelona. Hospital Vall D; España Fil: Montes, Melania. Universidad Autonoma de Barcelona. Hospital Vall D; España Fil: Garcia, Marta. Universidad Autonoma de Barcelona. Hospital Vall D; España Fil: Cabrera, Sílvia. Universidad Autonoma de Barcelona. Hospital Vall D; España Fil: Gil Moreno, Antonio. Universidad Autonoma de Barcelona. Hospital Vall D; España Fil: Xercavins, Jordi. Universidad Autonoma de Barcelona. Hospital Vall D; España Fil: Castellví, Josep. Universidad Autonoma de Barcelona. Hospital Vall D; España Fil: Garcia, Angel. Universidad Autonoma de Barcelona. Hospital Vall D; España Fil: Ramón y Cajal, Santiago. Universidad Autonoma de Barcelona. Hospital Vall D; España Fil: Moreno, Gema. Fundación MD Anderson; España Fil: Alameda, Francesc. Hospital del Mar. Servei de Patologia ; España Fil: Vazquez, Monica Hebe. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); Argentina. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Centro Cientifico Tecnológico Bahia Blanca. Instituto de Ciencias Biologicas y Biomedicas del Sur; Argentina Fil: Palacios, José. Universidad Autonoma de Barcelona. Hospital Vall D; España Fil: Prat, Jaime. Hospital de la Santa Creu i Sant Pau. Servei de Patologia; España Fil: Doll, Andreas. Universidad Autonoma de Barcelona. Hospital Vall D; España Fil: Matías Guiu, Xavier. Hospital Arnau de Vilanova. Servei de Patologia; España Fil: Abal, Miguel. Complejo Hospitalario de Santiago de Compostela; España Fil: Reventós, Jaume. Universidad Autonoma de Barcelona. Hospital Vall D; España |
| description |
Endometrial carcinoma (EC) is the most commonly diagnosed gynecologic malignancy in the western world. The majority of these cancers are curable, but a subset about 15–20% of endometrial tumors exhibits an aggressive phenotype. Based on clinic-pathological and molecular characteristics, EC has been classified into two groups: Type I estrogen-dependent adenocarcinomas, which have a good prognosis and an endometrioid histology, and Type II or non-estrogen-dependent EC associated with poor prognosis and non-endometrioid histology. EC develops as a result of a stepwise accumulation of alterations that seem to be specific of each histological type. However, more knowledge is needed to better understand the differences in the biology and the clinical outcome of EC. We would like to highlight the need to explore new potential biomarkers of EC as a tool for the detection and monitoring of aggressive endometrial tumors that, at the same time, will allow us to develop novel and more selective molecular targeted therapies against EC. |
| publishDate |
2011 |
| dc.date.none.fl_str_mv |
2011-10 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/11208 Llauradó, Marta; Ruiz, Anna; Majem, Blanca; Ertekin, Tugce; Colás, Eva; et al.; Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and therapy of the disease; Elsevier Ireland; Molecular And Cellular Endocrinology; 358; 2; 10-2011; 244-255 0303-7207 |
| url |
http://hdl.handle.net/11336/11208 |
| identifier_str_mv |
Llauradó, Marta; Ruiz, Anna; Majem, Blanca; Ertekin, Tugce; Colás, Eva; et al.; Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and therapy of the disease; Elsevier Ireland; Molecular And Cellular Endocrinology; 358; 2; 10-2011; 244-255 0303-7207 |
| dc.language.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S0303720711005892 info:eu-repo/semantics/altIdentifier/doi/10.1016/j.mce.2011.10.003 |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
| dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
Elsevier Ireland |
| publisher.none.fl_str_mv |
Elsevier Ireland |
| dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
| reponame_str |
CONICET Digital (CONICET) |
| collection |
CONICET Digital (CONICET) |
| instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
| _version_ |
1842269286495682560 |
| score |
13.13397 |